Suzanne Hitchcock‐Bryan

1.2k total citations
10 papers, 913 citations indexed

About

Suzanne Hitchcock‐Bryan is a scholar working on Public Health, Environmental and Occupational Health, Pediatrics, Perinatology and Child Health and Oncology. According to data from OpenAlex, Suzanne Hitchcock‐Bryan has authored 10 papers receiving a total of 913 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Public Health, Environmental and Occupational Health, 3 papers in Pediatrics, Perinatology and Child Health and 3 papers in Oncology. Recurrent topics in Suzanne Hitchcock‐Bryan's work include Acute Lymphoblastic Leukemia research (6 papers), Childhood Cancer Survivors' Quality of Life (3 papers) and Ethics in Clinical Research (2 papers). Suzanne Hitchcock‐Bryan is often cited by papers focused on Acute Lymphoblastic Leukemia research (6 papers), Childhood Cancer Survivors' Quality of Life (3 papers) and Ethics in Clinical Research (2 papers). Suzanne Hitchcock‐Bryan collaborates with scholars based in United States and Tunisia. Suzanne Hitchcock‐Bryan's co-authors include Richard D. Gelber, J. Robert Cassady, Stephen E. Sallan, SE Sallan, Nancy J. Tarbell, S. Blattner, Ramana Tantravahi, Harvey J. Cohen, Pearl Leavitt and Luis A. Clavell and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Suzanne Hitchcock‐Bryan

10 papers receiving 883 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Suzanne Hitchcock‐Bryan United States 8 555 322 242 177 152 10 913
Shinji Kishi Japan 14 421 0.8× 323 1.0× 207 0.9× 310 1.8× 226 1.5× 55 967
John M. Goldberg United States 11 235 0.4× 131 0.4× 190 0.8× 212 1.2× 711 4.7× 25 1.3k
Margaret Masterson United States 15 263 0.5× 137 0.4× 600 2.5× 285 1.6× 139 0.9× 41 930
Kate Wheeler United Kingdom 14 220 0.4× 159 0.5× 189 0.8× 96 0.5× 104 0.7× 30 668
Asim Belgaumi Saudi Arabia 18 293 0.5× 244 0.8× 151 0.6× 248 1.4× 305 2.0× 63 959
WE Evans United States 12 941 1.7× 609 1.9× 456 1.9× 222 1.3× 175 1.2× 13 1.2k
Robert O. Bash United States 11 173 0.3× 79 0.2× 109 0.5× 213 1.2× 240 1.6× 15 690
Siebold S.N. de Graaf Netherlands 18 686 1.2× 276 0.9× 965 4.0× 536 3.0× 352 2.3× 38 1.6k
Daniel M. Lane United States 15 298 0.5× 244 0.8× 134 0.6× 113 0.6× 103 0.7× 28 707
Eleanor V. Willett United Kingdom 14 272 0.5× 83 0.3× 184 0.8× 281 1.6× 331 2.2× 22 1.0k

Countries citing papers authored by Suzanne Hitchcock‐Bryan

Since Specialization
Citations

This map shows the geographic impact of Suzanne Hitchcock‐Bryan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suzanne Hitchcock‐Bryan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suzanne Hitchcock‐Bryan more than expected).

Fields of papers citing papers by Suzanne Hitchcock‐Bryan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suzanne Hitchcock‐Bryan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suzanne Hitchcock‐Bryan. The network helps show where Suzanne Hitchcock‐Bryan may publish in the future.

Co-authorship network of co-authors of Suzanne Hitchcock‐Bryan

This figure shows the co-authorship network connecting the top 25 collaborators of Suzanne Hitchcock‐Bryan. A scholar is included among the top collaborators of Suzanne Hitchcock‐Bryan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suzanne Hitchcock‐Bryan. Suzanne Hitchcock‐Bryan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Hoffner, Brianna, et al.. (2011). “Entering a clinical trial: Is it right for you?”. Cancer. 118(7). 1877–1883. 32 indexed citations
2.
Eder, Joseph P., Geoffrey I. Shapiro, Leonard J. Appleman, et al.. (2010). A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2. Clinical Cancer Research. 16(13). 3507–3516. 160 indexed citations
3.
Hitchcock‐Bryan, Suzanne, Brianna Hoffner, Steven Joffe, et al.. (2007). Entering a Clinical Trial: Is It Right For You?–A randomized study of the Clinical Trials Video and its impact on the informed consent process. Journal of Clinical Oncology. 25(18_suppl). 9072–9072. 1 indexed citations
4.
LoRusso, P., Leonard J. Appleman, Aiqin Zhu, et al.. (2006). 404 POSTER Pharmacodynamics (pd) of x1880, a novel spectrum selective kinase inhibitor (SSKI), administered orally to patients (pts) with advanced solid tumors (AST). European Journal of Cancer Supplements. 4(12). 124–124. 4 indexed citations
5.
Hitchcock‐Bryan, Suzanne, Richard D. Gelber, J. Robert Cassady, & Stephen E. Sallan. (1986). The impact of induction anthracycline on long‐term failure‐free survival in childhood acute lymphoblastic leukemia. Medical and Pediatric Oncology. 14(4). 211–215. 62 indexed citations
6.
Clavell, Luis A., Richard D. Gelber, Harvey J. Cohen, et al.. (1986). Four-Agent Induction and Intensive Asparaginase Therapy for Treatment of Childhood Acute Lymphoblastic Leukemia. New England Journal of Medicine. 315(11). 657–663. 330 indexed citations
7.
Niemeyer, CM, Suzanne Hitchcock‐Bryan, & SE Sallan. (1985). Comparative analysis of treatment programs for childhood acute lymphoblastic leukemia.. PubMed. 12(2). 122–30. 72 indexed citations
8.
Sallan, SE, et al.. (1983). Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia.. PubMed. 43(11). 5601–7. 160 indexed citations
9.
10.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shinji Kishi Breakdown of academic impact, for papers by John M. Goldberg Breakdown of academic impact, for papers by Margaret Masterson Breakdown of academic impact, for papers by Kate Wheeler Breakdown of academic impact, for papers by Asim Belgaumi Breakdown of academic impact, for papers by WE Evans Breakdown of academic impact, for papers by Robert O. Bash Breakdown of academic impact, for papers by Siebold S.N. de Graaf Breakdown of academic impact, for papers by Daniel M. Lane Breakdown of academic impact, for papers by Eleanor V. Willett
Rankless by CCL
2026